The use of scintigraphy to provide 'proof of concept' for novel polysaccharide preparations designed for colonic drug delivery

Pharmaceutical Research

Volumn 14, Issue 1, 1997, Pages 103-107

  Adkin, Dawn A ^a   Kenyon, Carole J ^a   Lerner, E Itzhack ^b   Landau, Isaac ^b   Strauss, Eric ^b   Caron, David ^b   Penhasi, Adel ^b   Rubinstein, Abraham ^c   Wilding, Ian R ^a  

^a PHARMACEUTICAL PROFILES LTD   (United Kingdom)

^b Perio Products Ltd   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

'Proof of concept'; Calcium pectinate; Colon targeting; Gamma scintigraphy

Indexed keywords

CALCIUM PECTINATE; GUAR GUM; PECTIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL TISSUE; ARTICLE; CLINICAL TRIAL; COLON; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; FEMALE; GAMMA SCINTIGRAPHY; GASTROINTESTINAL TRANSIT; HUMAN; HUMAN EXPERIMENT; MALE; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; SINGLE BLIND PROCEDURE; TABLET DISINTEGRATION; TABLET FORMULATION;

ADULT; ANIMALS; CROSS-OVER STUDIES; DRUG DELIVERY SYSTEMS; FEMALE; GALACTANS; GASTROINTESTINAL TRANSIT; HUMANS; ILEOCECAL VALVE; ISOTOPE LABELING; MALE; MANNANS; MIDDLE AGED; PECTINS; PLANT GUMS; RATS; STOMACH; TABLETS, ENTERIC-COATED;

EID: 0031042162     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012019820603     Document Type: Article

References (19)

1. A. Rubinstein, Crit. Rev. Ther. Drug Carr. Sys., 12:101-149 (1995).
2. V. H. L. Lee. Pharm. Tech. Int. 10:59-62 (1992).
3. P. Gruber, M. A. Longer, and J. R. Robinson. Adv. Drug De. Rev. 1:1-18 (1987).
4. W. A. Ritschel. Methods Find. Exp. Clin. Pharmacol. 13:313-336 (1991).
5. M. J. Dew, P. J. Hughes, M. G. Lee, B. K. Evans, and J. Rhodes. Br. J. Pharmacol. 14:405-408 (1982).
6. M. Saffran, G. S. Kumar, C. Savariar, D. C. Neckers, J. Pena, R. H. Jones, and J. B. Field. Biochem. Soc. Trans. 18:752-754 (1990).
7. D. R. Friend and G. W. Chang. J. Med. Chem. 27:261-266 (1984).
8. A. Rubinstein, D. Nakar, and A. Sintov. Pharm. Res. 9:276-278 (1992).
9. A. Rubinstein, R. Radai, M. Ezra, S. Pathak, and J. S. Rokea. Pharm. Res. 10:258-263 (1993).
10. M. Ashford, J. T. Fell, D. Attwood, H. Sharma, and P. J. Wood. J. Com. Rel. 30:225-232 (1994).
11. H. N. Englyst, S. Hay, and G. T. Macfarlane. FEMS Microbiol. Ecol. 95:163-171 (1987).
12. I. R. Wilding. STP Pharma. Sci. 5:13-18 (1995).
13. I. R. Wilding, A. J. Coupe, and S. S. Davis. Adv. Drug Del. Rev. 7:87-117 (1991).
14. G. T. Macfarlane, S. Hay, S. Macfarlane, and G. R. Gibson. Appl. Bacteriol. 68:179-187 (1990).
15. J. Kopecek, P. Kopeckova, H. Brondsted, R. Rathi, R. Rihova, P.-Y. Yeh, and K. Ikesue. J. Contr. Rel. 19:121-130, (1992).
16. D. A. Adkin, S. S. Davis, R. A. Sparrow, and I. R. Wilding. J. Contr. Rel. 23:147-156 (1993).
17. G. Hawksworth, B. S. Drasar, and M. J. Hill. J. Med. Microbiol., 4:451 (1971).
18. S. S. Davis, J. G. Hardy, and J. W. Fara. Gut 27:886-892 (1986).
19. A. Rubinstein and I. Gliko-Kabir. S.T.P. Pharma. Sci. 5:41-46 (1995).